Bristol-Myers Squibb Says Orencia Approved by EU
Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.